To view the PDF file, sign up for a MySharenet subscription.

MEDICLINIC INTERNATIONAL PLC - Notification of transactions by persons discharging managerial responsibilities and persons closely associated

Release Date: 31/07/2020 16:00
Code(s): MEI     PDF:  
Wrap Text
Notification of transactions by persons discharging managerial responsibilities and persons closely associated

Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
("Mediclinic", or the "Company", or the "Group")

31 July 2020

Replacement: The following announcement replaces the announcement released on 17 June
2020 at 3.30pm (UK) under RNS number 2768Q. The amount settled per share and the cash
settlements (including dividend equivalents) have been amended. The corrected announcement
is set out below and all other details remain unchanged.

NOTIFICATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL
RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

This notification sets out details of the vesting and settlement of awards granted to the executive
directors on 15 June 2018 in respect of the deferred element of the Company’s 2017 short-term
incentive (“STI”). These awards, denominated in shares, vested on 15 June 2020 and will be settled in
cash on 26 June 2020 based on the middle-market quotation of a share on 15 June 2020, being £2.68
per share. The amount settled included the value of dividends attributable to the vested shares during
the period between the date of grant and the date of vesting, being a total of 15.8 pence per share.

The table below sets out the number of shares vested for the directors who were granted awards under
the STI on 15 June 2018 together with the corresponding cash settlement.

Name                                     Number of shares vested                 Cash settlement
                                                                                (including dividend
                                                                                 equivalents)
Petrus Jurgens Myburgh1                          27 236                              £77,350
Daniël Petrus   Meintjes2                        45 811                              £130,103

Notes:
1 As Group Chief Financial Officer, Mr Myburgh is required to build and maintain a minimum holding of shares
equivalent to a value of 200% of his annual base compensation. As that threshold had not been met under the
Company’s Remuneration Policy, Mr Myburgh was required to apply 50% of the net of tax value of the vested
shares to the purchase of ordinary shares in Mediclinic. As announced on 10 June 2020, Mr Myburgh purchased
7 500 shares on 8 June 2020 to fulfil this obligation.
2 Mr Meintjes was an executive director of the Company at the time the award was granted and is now a non-
executive director.

The notifications below are made in accordance with Articles 19.1 and 19.3 of the Market Abuse
Regulation.

1.   Details of PDMR / person closely associated with them ("PCA")
a)   Name                        Petrus Jurgens Myburgh

2.   Reason for the notification
a)   Position / status           Group Chief Financial Officer of the Company
b)   Initial notification / Initial Notification
     amendment
3.   Details of the issuer, emission allowance market participant, auction platform, auctioneer or
     auction monitor
a)   Name                        Mediclinic International plc
b)   LEI                         2138002S5BSBIZTD5I60

4.   Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each
     type of transaction; (iii) each date; and (iv) each place where transactions have been
     conducted
a)   Description of the          Ordinary shares
     financial instrument
     Identification Code         GB00B8HX8Z88
b)   Nature of the               Vesting and cash settlement of award over ordinary shares in
     transaction                 Mediclinic International plc granted in 2018 under the
                                 Company’s short-term incentive scheme
c)   Price(s) and
     volume(s)                   Price(s)                         Volume(s)
                                 £nil                              27 236
d)   Aggregated
     information
     Aggregated volume           27 236
     Price                       £nil
e)   Date of the                 15 June 2020
     transaction
f)   Place of the                Outside a trading venue
     transaction

1.   Details of PDMR / person closely associated with them (“PCA”)
a)   Name                        Daniël Petrus Meintjes

2.   Reason for the notification
a)   Position / status           Non-executive director of the Company
b)   Initial notification /      Initial Notification
     amendment
3.   Details of the issuer, emission allowance market participant, auction platform, auctioneer or
     auction monitor
a)   Name                        Mediclinic International plc
b)   LEI                         2138002S5BSBIZTD5I60

4.   Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each
     type of transaction; (iii) each date; and (iv) each place where transactions have been
     conducted
a)   Description of the          Ordinary shares
     financial instrument
     Identification Code         GB00B8HX8Z88
b)   Nature of the               Vesting and cash settlement of award over ordinary shares in
     transaction                 Mediclinic International plc granted in 2018 under the
                                 Company’s short-term incentive scheme
c)   Price(s) and
     volume(s)                   Price(s)                         Volume(s)
                                 £nil                              45 811
d)   Aggregated
     information
     Aggregated volume           45 811
     Price                       £nil
e)   Date of the                 15 June 2020
     transaction
f)   Place of the                Outside a trading venue
     transaction

About Mediclinic International plc

Mediclinic is a diversified international private healthcare services group, established in South Africa in
1983, with divisions in Switzerland, Southern Africa (South Africa and Namibia) and the United Arab
Emirates ("UAE").

The Group’s core purpose is to enhance the quality of life.

Its vision is to be the partner of choice that people trust for all their healthcare needs.

Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the continuum
of care in such a way that the Group will be regarded as the most respected and trusted provider of
healthcare services by patients, medical practitioners, funders and regulators of healthcare in each of
its markets.

At 1 July 2020, Mediclinic comprised 76 hospitals, eight sub-acute and specialised hospitals, 15 day
case clinics and 18 outpatient clinics. Hirslanden operated 17 hospitals and three day case clinics in
Switzerland with more than 1 800 inpatient beds; Mediclinic Southern Africa operations included 52
hospitals (three of which in Namibia), eight sub-acute and specialised hospitals and 10 day case clinics
(four of which operated by Intercare) across South Africa, and more than 8 700 inpatient beds; and
Mediclinic Middle East operated seven hospitals, two day case clinics and 18 outpatient clinics with
more than 900 inpatient beds in the UAE.

The Company’s primary listing is on the London Stock Exchange ("LSE") in the UK, with secondary
listings on the JSE Ltd in South Africa and the Namibian Stock Exchange in Namibia.

Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a leading private healthcare group
based in the UK and listed on the LSE.

For further information, please contact:

Company Secretary, Link Company Matters Limited
Kerry Higgins
+44 (0) 20 7954 9583

Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181

Media queries
FTI Consulting
Ben Atwell/Ciara Martin – UK
+44 (0)20 3727 1000
Sherryn Schooling – South Africa
+27 (0)21 487 9000

Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom
Website: www.mediclinic.com
Corporate broker: Morgan Stanley & Co International plc and UBS Investment Bank
JSE sponsor (South Africa): Rand Merchant Bank (A division of FirstRand Bank Limited)
NSX sponsor (Namibia): Simonis Storm Securities (Pty) Ltd

Date: 31-07-2020 04:00:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.

Share This Story